Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06088303 · ClinicalTrials.gov registry record · NA

Enhancing PTSD Treatment Outcomes by Improving Patient-Provider Communication

A NA study of Stress Disorders, Post-Traumatic, sponsored by Boston University.

Recruiting
Registry status
NA
Development phase
54
Enrollment target
1
Study location

NCT06088303: Recruiting NA study of Stress Disorders, Post-Traumatic, sponsored by Boston University.

NCT06088303 is a NA study of Stress Disorders, Post-Traumatic that is actively recruiting participants, run by Boston University. The registered enrollment target is 54 participants, below the 155-participant average among 66 other Stress Disorders, Post-Traumatic trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06088303, a NA study of Stress Disorders, Post-Traumatic, is actively recruiting participants, sponsored by Boston University.

RECRUITING
Registry status
NA
Development phase
54 participants
Enrollment target
1
Study location

Study Summary

The purpose of this clinical trial is to learn whether existing treatments for posttraumatic stress disorder (PTSD) can be improved. Two treatments for PTSD, cognitive processing therapy (CPT) and prolonged exposure (PE) will be studied. CPT and PE are effective treatments that are widely available, but interventions are needed to improve patient outcomes in these treatments. The investigators have developed an Adjunctive Writing intervention for Amplifying Response and Engagement (AWARE), which was designed using health communication strategies to enhance CPT and PE by improving communication between patients and therapists about patients' experiences in treatment. This research will investigate whether adding AWARE to CPT and PE will lead to better treatment outcomes compared to CPT and PE provided as usual without AWARE. AWARE includes a brief writing task asking patients about their experiences in treatment, as well as guided therapist responses to improve patient-therapist communication about patients' experiences in treatment. In the first phase of the study (case series phase), CPT or PE with AWARE will be provided to four adults with PTSD to pilot test adding AWARE to CPT and PE, seek patient and provider feedback, and refine AWARE. The first four participants who enroll will be part of the case series and will receive CPT or PE with AWARE. Then, in the second phase of the study, the randomized controlled trial (RCT) phase, the investigators will enroll 50 more adults with PTSD who will be randomly assigned (like flipping a coin) to receive CPT/PE as usual or CPT/PE with AWARE. It is expected that 25 participants will be randomized to CPT/PE with AWARE and 25 participants will be randomized to receive CPT/PE provided as usual. The goals of the RCT phase are to study whether AWARE is acceptable to patients, whether it is feasible to add AWARE to CPT and PE, and whether adding AWARE to CPT and PE improves patient-therapist communication and treatment outcomes

Primary Outcome

Verona Coding Definitions of Emotional Sequences (VR-CoDES) - Observational Coding - Used to code patient writing and recordings of each weekly session check-in for 1) patient disclosure of concerns and 2) therapists' responses to patients' concerns. A random selection of 25% of session recordings will be rated. Patients' cues and concerns and providers' responses to patients' cues and concerns are classified into 25 categories, coded as present/absent. Codes will be averaged across all treatmen

Interventions

  • BEHAVIORAL Adjunctive writing to amplify response and engagement (AWARE)
  • BEHAVIORAL Cognitive processing therapy (CPT)
  • BEHAVIORAL Prolonged exposure (PE)

Study Locations (1)

Massachusetts

  • National Center for PTSD at VA Boston Healthcare System - Boston

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2025-01-15
Est. Completion 2028-12-31
Phase NA
Boston University

185 total trials

What NCT06088303 shows while recruiting

NCT06088303 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 155-participant average among 66 other Stress Disorders, Post-Traumatic trials with a reported enrollment target (65% lower).

The record links to 1 condition, with Stress Disorders, Post-Traumatic appearing as the primary indexed condition, and to 3 interventions - of which Adjunctive writing to amplify response and engagement (AWARE) is the first listed.

NCT06088303 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06088303 about?

NCT06088303 is a clinical study titled "Enhancing PTSD Treatment Outcomes by Improving Patient-Provider Communication". The purpose of this clinical trial is to learn whether existing treatments for posttraumatic stress disorder (PTSD) can be improved. Two treatments for PTSD, cognitive processing therapy (CPT) and prolonged exposure (PE) will be studied. CPT and PE are effective treatments that are widely available,...

What is the current status of trial NCT06088303?

This trial is currently recruiting. It is a NA study. The enrollment target is 54 participants. The study started on 2025-01-15. Estimated completion is 2028-12-31.

What conditions does trial NCT06088303 study?

This clinical trial studies the following conditions: Stress Disorders, Post-Traumatic.

What interventions are being tested in trial NCT06088303?

The interventions under investigation include: Adjunctive writing to amplify response and engagement (AWARE) (BEHAVIORAL), Cognitive processing therapy (CPT) (BEHAVIORAL), Prolonged exposure (PE) (BEHAVIORAL).

Who is sponsoring clinical trial NCT06088303?

This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06088303 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stress Disorders, Post-Traumatic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06088303's enrollment target sits among peer trials

54 48th of 66 higher than 19 of 66 other Stress Disorders, Post-Traumatic trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stress Disorders, Post-Traumatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01269853 · 54 participants · Phase 1

    Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

  • NCT02390752 · 54 participants · Phase 1

    Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

  • NCT02991248 · 54 participants · NA

    Improve Dynamic Lateral Balance of Humans With SCI

  • NCT02993900 · 54 participants · NA

    Image-Guided Gynecologic Brachytherapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06088303, the US trial registry maintained by the National Library of Medicine. NCT06088303 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.